Hematology remains at the forefront of medical innovation, driving breakthroughs in understanding and treating blood-related disorders that affect millions worldwide. This dynamic field encompasses cutting-edge research in hematopoiesis, hemostasis, transfusion medicine, and the molecular mechanisms underlying conditions ranging from anemia to hematologic malignancies.

MDPI’s cluster of hematology journals has the mission to publish recent advances in this field that have profound implications for a broad spectrum of disorders, including anemia, leukemias, and rare blood conditions. These journals aim to offer the most up-to-date research and discoveries within the field of hematology to the broader scientific community.

The four participating journals are as follows:

• Hemato (ISSN: 2673-6357) is an integrative effort to explore the multifaceted nature of hematologic diseases, leukemias, and lymphomas. The journal aims to document scientific advancements and provide insights to enhance patient care. It emphasizes immunologic and genetic biomarkers, while also addressing refractory and early relapsed diseases, covering topics from microscopic morphology to immune therapies, ultimately aiming to improve patient outcomes. Hemato is led by its Editor-in-Chief, Prof. Dr. Antonino Carbone;
• Hematology Reports (ISSN: 2038-8330) investigates the prevention, diagnosis, and management of blood disorders, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and controlled trials. Hematology Reports is led by its Editor-in-Chief, Dr. Claudio Cerchione;
• Thalassemia Reports (ISSN: 2039-4365) analyzes the pathophysiology, diagnosis, classification, and treatment of thalassemia and related disorders for physicians and medical scientists. The journal publishes clinically relevant information that aims to directly improve the care of patients with thalassemia. Basic science studies of interest to clinicians are also considered for publication, when relevant. Specific case reports are also welcome, particularly those including detailed clinical profiles of patients. Thalassemia Reports is led by its Editor-in-Chief, Prof. Dr. Aurelio Maggio;
• Journal of Clinical Medicine (ISSN: 2077-0383) covers all aspects of clinical and pre-clinical research. JCM is led by its Editors-in-Chief, Prof. Dr. Emmanuel Andrès and Prof. Dr. Kent Doi. The journal also features a Section “Hematology”, which provides novel information and groundbreaking updates on clinical and laboratory hematology, from clinical trials to real-world clinical practice.

	Launch Year	Impact Factor (2023)	CiteScore (2023)	First Decision (Median)	APC
	2020	0.9	1.3	30.6 days	CHF 1000
	2009	1.1	0.9	39.1 days	CHF 1600
	2011	0.6	/	33.1 days	CHF 1000
	2012	3.0	5.7	16 days	CHF 2600

MDPI mission and values:
As a pioneer in academic open access publishing, MDPI has been serving the scientific community since 1996. Our aim is to foster scientific exchange in all forms and across all disciplines. MDPI's guidelines for disseminating open science are based on the following values and guiding principles:

• Open Access—All our content is published in open access and distributed under a Creative Commons License, providing free access to science and the latest research, allowing articles to be freely shared and content to be re-used with proper attribution;
• Timeliness and Efficiency—The latest research is rapidly published through a thorough editorial process, ensuring that a first decision is provided to authors in under 32 days and that papers are published within 7–10 days upon acceptance;
• Simplicity—We offer user-friendly tools and services in one place to enhance the efficiency of our editorial process;
• High-Quality Service—We support scholars and their work by providing a range of options, such as journal publication at mdpi.com, early publication at preprints.org, and conferences on sciforum.net, to make a positive impact on research;
• Flexibility—We adapt and develop new tools and services to meet the changing needs of the research community, driven by feedback from authors, editors, and readers;
• Rooted in Sustainability—We ensure the long-term preservation of published papers and support the future of science through partnerships, sponsorships, and awards.

By adhering to these values and principles, MDPI remains committed to advancing scientific knowledge and promoting open science practices.

Selected Topics and Special Issues:

• “Advances in Molecular Pathogenesis and Targeted Therapies for Multiple Myeloma”
• “Hematopathology: Rare Hematological Diseases”
• “Anaemia in Focus: Challenges and Solutions in Haematology”
• “Innovative Therapies and Management of Complications in Hemoglobinopathies”

Selected Articles:
Journal of Clinical Medicine
“Imaging of Multiple Myeloma: Present and Future”
J. Clin. Med. 2024, 13(1), 264; https://doi.org/10.3390/jcm13010264

Thalassemia Reports
“CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia”
Thalass. Rep. 2023, 13(1), 51-69; https://doi.org/10.3390/thalassrep13010006

Hemato
“Artificial Intelligence, Lymphoid Neoplasms, and Prediction of MYC, BCL2, and BCL6 Gene Expression Using a Pan-Cancer Panel in Diffuse Large B-Cell Lymphoma”
Hemato 2024, 5(2), 119-143; https://doi.org/10.3390/hemato5020011

Hematology Reports 
“A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia”
Hematol. Rep. 2024, 16(2), 244-254; https://doi.org/10.3390/hematolrep16020024